Birmingham Capital Management Co. Inc. AL Has $4.14 Million Stake in Pfizer Inc. $PFE

Birmingham Capital Management Co. Inc. AL decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 6.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,243 shares of the biopharmaceutical company’s stock after selling 10,344 shares during the quarter. Pfizer makes up approximately 1.6% of Birmingham Capital Management Co. Inc. AL’s portfolio, making the stock its 24th biggest position. Birmingham Capital Management Co. Inc. AL’s holdings in Pfizer were worth $4,137,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Triumph Capital Management raised its position in shares of Pfizer by 20.0% during the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 1,717 shares during the last quarter. Gotham Asset Management LLC lifted its stake in shares of Pfizer by 333.4% in the fourth quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock worth $3,742,000 after acquiring an additional 108,494 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Pfizer by 80.7% in the fourth quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock valued at $25,434,000 after acquiring an additional 427,886 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.59 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The firm has a market capitalization of $139.79 billion, a price-to-earnings ratio of 13.08, a PEG ratio of 0.88 and a beta of 0.55. The business has a 50-day simple moving average of $24.83 and a 200 day simple moving average of $24.33. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s payout ratio is currently 91.49%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. HSBC dropped their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Finally, Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.